Thera-SAbDab

OPORTUZUMAB

> Structural Summary

Therapeutic	Oportuzumab
Target	EPCAM
Heavy Chain	EVQLVQSGPGLVQPGGSVRISCAASGYTFTNYGMNWVKQAPGKGLEWMGWINTYTGESTYADSFKGRFTFSLDTSASAAYLQINSLRAEDTAVYYCARFAIKGDYWGQGTLLTVSS
Light Chain	DIQMTQSPSSLSASVGDRVTITCRSTKSLLHSNGITYLYWYQQKPGKAPKLLIYQMSNLASGVPSRFSSSGSGTDFTLTISSLQPEDFATYYCAQNLEIPRTFGQGTKVELK
100% seqID Fv Structure	None
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

There are currently no PDB structures close in sequence to this therapeutic Fv. Click here to build a model with ABodyBuilder.

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	scFv
Isotype	na
Highest Clinical Trial (June '19)	Preregistration
Estimated Status (June '19)	Active
Recorded Developmental Technology	na
INN Year Proposed	2008
INN Year Recommended	2009
Companies Involved	University of Zurich, National Cancer Institute (USA), Sesen Bio, Viventia Biotechnologies
Conditions Approved	na
Conditions Active	Bladder cancer, Head and neck cancer
Conditions Discontinued	Liver cancer, Ovarian cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]